Enshuxing (enlonstobart)

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)

SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer (clinicaltrials.gov)

A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer (clinicaltrials.gov)

Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC (clinicaltrials.gov)

An open-label, multicenter, phase II study to evaluate the efficacy and safety of SYS6010 combined with enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma (ChiCTR2500112871)

Phase II/III Trial of SYS6010 plus Enlonstobart Injection ± Chemotherapy in Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ChiCTR2500112440)

A single-Arm, Open-Label Ib/II Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma(PTCL) (ChiCTR2500111610)

Phase I/II clinical study of SYS6043 combined with PD-1/PD-L1 inhibitor ± chemotherapy in the treatment of advanced solid tumor participants (ChiCTR2500112838)

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov)

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer (clinicaltrials.gov)

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) (clinicaltrials.gov)